Entry Point Capital, LLC Coherus Bio Sciences, Inc. Transaction History
Entry Point Capital, LLC
- $171 Million
- Q3 2024
Shares
1 transactions
Others Institutions Holding CHRS
# of Institutions
135Shares Held
77.9MCall Options Held
40.7KPut Options Held
50.1K-
Black Rock Inc. New York, NY11.8MShares$17.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.3MShares$16.7 Million0.0% of portfolio
-
Rubric Capital Management LP New York, NY10.4MShares$15.4 Million0.3% of portfolio
-
Kohlberg Kravis Roberts & Co. L.P. New York, NY3.04MShares$4.49 Million0.18% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.86MShares$4.23 Million0.0% of portfolio
About Coherus BioSciences, Inc.
- Ticker CHRS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,724,600
- Market Cap $115M
- Description
- Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...